EASL-柳叶刀肝脏委员会呼吁欧洲应对肝脏疾病的范式转变

StephenW

EASL-柳叶刀肝脏委员会呼吁欧洲应对肝脏疾病的范式转变

在 12 月 3 日发布的一份报告中，EASL-柳叶刀肝脏委员会表示，欧洲的肝脏反应需要进行范式转变，以解决导致欧洲失去工作多年的第二大原因。

医学界需要改变对肝病的态度：与其关注终末期并发症的管理，不如转向预防、主动发现病例、早期识别进展性肝纤维化、早期诊断和早期治疗， EASL-柳叶刀肝脏委员会在一份新闻声明中说。

除了强调筛查肝病、预防和早期治疗病毒性肝炎的重要性外，该报告还建议在整个欧洲采取一致的公共卫生政策，旨在减少酒精、高脂肪和高糖食品的消费，对抗酒精性和非酒精性脂肪肝。

EASL-Lancet 肝脏委员会的主要建议：

    实施标准化和简化的肝脏血液检测，以便早期发现和及时护理。
    利用乙型和丙型肝炎药物以及乙型和甲型肝炎疫苗创造的机会在欧洲实现消除病毒性肝炎。
    提高认识并为初级保健同行和专业人员提供经济奖励。
    非病毒性肝病必须与其他非传染性疾病一起分类，以采用适当的护理模式。
    必须反对对有肝病风险或患有肝病的人的所有形式和污名化的来源——医学术语的相关变化应该放在首位。
    在整个欧洲公开披露抗病毒药物的价格将加强世卫组织/世界卫生大会的决议，以提高市场价格的公平性。
    欧洲各国政府必须出台统一政策以减少有害使用酒精。
    全面禁止社交和数字媒体营销针对儿童的酒精和超加工、高脂肪和高糖食品。
    通过补贴健康食品，促进行业主导的食品重新配方和最小化社会不平等。
    欧盟和欧洲政府应优先协调整个欧洲的公共卫生干预措施和与健康相关的政策的关键形式。

StephenW

EASL-Lancet Liver Commission calls for a paradigm shift in European responses to liver disease

In a report issued on 3 December, the EASL-Lancet Liver Commission said a paradigm shift is needed in the liver response in Europe to tackle the second-biggest cause of years of working life lost in Europe.

The medical profession needs to change its approach to liver disease: instead of focusing on the management of end-stage complications, it needs to shift towards prevention, proactive case-finding, with early identification of progressive liver fibrosis, early diagnosis and early treatment, the EASL-Lancet Liver Commission said in a press statement.

As well as emphasising the importance of screening for liver disease, prevention and early treatment of viral hepatitis, the report also recommends the adoption of consistent public health policies across Europe designed to reduce the consumption of alcohol, high-fat and high-sugar foods, to combat alcoholic and non-alcoholic fatty liver disease.

Key recommendations of the EASL-Lancet Liver Commission:

    Implementation of standardised and simplified liver blood tests for earlier detection and prompt care.
    Utilisation of opportunities created by the hepatitis B and C drugs as well as hepatitis B and A vaccines to achieve viral hepatitis elimination in Europe.
    Increase awareness and provide financial incentives for primary care peers and professionals.
    Non-viral liver diseases must be classified along with other non-communicable diseases to engage appropriate care models.
    All forms and sources of stigma towards people at risk of or with liver disease must be opposed – relevant changes to the medical nomenclature should come first.
    Public disclosure of prices for antiviral drugs throughout Europe would reinforce the WHO/World Health Assembly resolution to improve fairness of market prices.
    European governments must introduce uniform policies to reduce the harmful use of alcohol.
    A complete social and digital media ban on the marketing of alcohol and ultra-processed, high-fat and high-sugar foods targeted to children.
    Promote industry-led food reformulation and minimisation of social inequities by subsidising healthy foods.
    EU and European governments should prioritise the harmonisation of critical forms of public health interventions and health-related policies across Europe.